GLP-1s in Hip and Knee Arthroplasty

Opening soon Phase 4 NCT07755085

Run by Nova Scotia Health Authority · for 18 to 90 · All sexes

What this study is about

The number of people living with hip and knee arthritis continues to grow. A large amount of these people are also overweight and diagnosed with obesity. Obesity leads to more stress on hip and knee joints, causing them to wear out sooner. This process is called arthritis. When arthritis gets worse, the joints often need to be replaced due to pain and poor mobility. Very heavy patients often have other health problems that can impair the ability to manage arthritis. Excess weight and health problems can change the way heavy patients recover after surgery, leading to a greater risk of complications. A new type of medicine might be able to improve how obese patients manage their hip and knee pain, as well as improve outcomes after surgery. This type of medicine is called a GLP-1. Investigators will study 2 groups, with one receiving the medicine while the other does not. The goal is to understand how these medications work in the time leading up to surgery and in the early postoperative recovery phase. If these medications help, it may improve the care of high risk obese patients.

Who can join (things the study team will check)

✅ You may be able to join if…

Patients with a diagnosis of hip or knee arthritis and are a deemed candidate for THA or TKA by an orthopaedic surgeon
Diagnosis of BMI 35+ with an obesity-related health condition (Coronary vascular disease, previous stroke, type 2 diabetes, hypertension, dyslipidemia, obstructive sleep apnea, asthma) or BMI 40+
Patients must be between 18-90 years of age
Able to provide informed consent

🚫 You may not be able to join if…

Cognitive impairment that precludes study participation and compliance
Patients unwilling to undergo smoking cessation prior to surgery
Patients currently taking biologic medications that suppress the immune system
Patients currently taking GLP-1 medications
Patients with a contraindication to GLP-1 medication

Where this trial is running

Nova Scotia Health, Dartmouth, Nova Scotia, Canada

Who to contact

Jhase Sniderman, MD, MSc, FRCSC, FAAOS · 9029323130 · jhase.sniderman@nshealth.ca

It's completely normal to call and ask questions before deciding anything. Mention the study ID: NCT07755085.

Open the interactive checklist for this trial →

Verify everything on the official ClinicalTrials.gov record. Page updated September 2026.

Beacon is an information tool, not medical advice. Whether a trial is right for you is a decision for you, your doctor, and the study team. Trial details come from the official registry, ClinicalTrials.gov, and may change — always confirm with the study team. Beacon collects no data about you: this page has no cookies, no accounts, and no tracking.